GENERAL27 Sept 2026
Capacity scale-ups to drive Epigral's ₹5,000 crore target by FY31: CMD
Epigral is doubling its CPVC resin and epichlorohydrin (ECH) capacity at Dahej, and targets ₹5,000 crore revenue by 2030-31. The specialty chemicals maker expects ₹2,900 crore this fiscal year, up from ₹2,500-2,530 crore in FY26. The ₹650 crore expansion, funded internally, starts adding revenue next year. If you buy these import-substitute chemicals, watch for better domestic supply and pricing.
Key Statutory Highlights
- Epigral plans to double its CPVC resin capacity from 75,000 TPA to 1,50,000 TPA.
- Its epichlorohydrin (ECH) capacity is being doubled from 50,000 TPA to 1,00,000 TPA at Dahej, Gujarat.
- The ₹650 crore spent on both expansions was raised entirely through internal accruals, and the plants are expected to be commissioned within a couple of months.
Actionable Advice for Taxpayers / Founders:If your business imports CPVC resin or ECH, review your sourcing plans and keep an eye on Epigral's expanded domestic supply, as it may offer an alternative to imports. This is not a guarantee of pricing or availability, so confirm details before changing suppliers.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: